资讯
PEDS trial shows tirzepatide delivers durable glycemic control and weight benefit in youth with type 2 diabetes, the first therapy to show this effect.
People with a common personality trait practiced by as many as one in five Americans may see fewer lasting results from GLP-1 ...
A recent study of nearly four million adults discovered that cannabis users experience up to four times the risk of ...
Participants in this year’s Community Farmacy program at Community Harvest Food Bank recorded notable improvements in their ...
Good Housekeeping on MSN
Can you be fat and fit? Here's everything you need to know about weight, fitness and health
If you’re living with overweight, is it possible to carry excess kilos without increasing your risk of long-term health ...
Data from two studies show greater weight loss and comparable safety with a higher dose of semaglutide for those with and ...
10 小时on MSN
Weight loss drug semaglutide shown to be safe and potentially more effective at higher dose ...
A higher dose of the weight loss drug semaglutide (better known by its brand name Wegovy) may help people lose up to 25% of ...
As part of a recent push to reduce or remove processed foods and ingredients from the nation’s food supply, Tyson Foods has ...
Discover a study exploring cardiovascular risk factors, lifestyle habits, and metabolic changes in adults with atopic ...
The Brighterside of News on MSN
Daily obesity pill Orforglipron helped adults lose up to 20% of their body weight in global ...
Obesity is one of the most stubborn health challenges of our time, linked with diabetes, heart disease, sleep problems, and ...
The drug. orforglipron, works on the same receptor as semaglutide (Ozempic/Wegovy), but can be taken without restrictions on food or water intake.
The results of this landmark trial are particularly significant, as oral therapies for obesity could improve both access to ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果